blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3226913

EP3226913 - DOPAMINE RECEPTOR TYPE 2 SPECIFIC PROMOTER AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.11.2020
Database last updated on 18.11.2024
FormerGrant of patent is intended
Status updated on  08.03.2020
FormerExamination is in progress
Status updated on  08.04.2019
FormerRequest for examination was made
Status updated on  08.09.2017
FormerThe international publication has been made
Status updated on  02.06.2017
Most recent event   Tooltip27.11.2020Application deemed to be withdrawnpublished on 30.12.2020  [2020/53]
Applicant(s)For all designated states
The Board of Trustees of the Leland Stanford Junior University
Office of the General Counsel
Building 170, Third Floor, Main Quad
P.O. Box 20386
Stanford, CA 94305-2038 / US
[2019/38]
Former [2017/41]For all designated states
The Board of Trustees of The Leland Stanford Junior University
Office of The General Counsel
Building 170, 3rd Floor, Main Quad
P.O. Box 20386
Stanford, CA 94305-2038 / US
Inventor(s)01 / DEISSEROTH, Karl A.
720 Alvarado Row
Stanford California 94305 / US
02 / RAMAKRISHNAN, Charu
6314 Paso Los Cerritos
San Jose California 95120 / US
03 / ZALOCUSKY, Kelly
1179 Boranda Avenue
Apt. 2
Mountain View California 94040 / US
 [2017/41]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2017/41]Green, Katherine, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15864812.103.12.2015
[2017/41]
WO2015US63804
Priority number, dateUS201462087603P04.12.2014         Original published format: US 201462087603 P
[2017/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016090172
Date:09.06.2016
Language:EN
[2016/23]
Type: A1 Application with search report 
No.:EP3226913
Date:11.10.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 09.06.2016 takes the place of the publication of the European patent application.
[2017/41]
Search report(s)International search report - published on:US09.06.2016
(Supplementary) European search report - dispatched on:EP03.04.2018
ClassificationIPC:A61K48/00, C12N15/866
[2017/41]
CPC:
C12N15/85 (EP,US); C07K14/43595 (US); C07K14/70571 (EP,US);
C12N9/1241 (EP,US); C12N2750/14143 (EP,US); C12N2830/008 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/41]
TitleGerman:FÜR DOPAMINREZEPTOR TYP 2 SPEZIFISCHER PROMOTOR UND VERFAHREN ZUR VERWENDUNG DAVON[2017/41]
English:DOPAMINE RECEPTOR TYPE 2 SPECIFIC PROMOTER AND METHODS OF USE THEREOF[2017/41]
French:PROMOTEUR SPÉCIFIQUE DU RÉCEPTEUR DE LA DOPAMINE DE TYPE 2 ET PROCÉDÉS POUR L'UTILISER[2017/41]
Entry into regional phase07.06.2017National basic fee paid 
07.06.2017Search fee paid 
07.06.2017Designation fee(s) paid 
07.06.2017Examination fee paid 
Examination procedure02.06.2017Date on which the examining division has become responsible
07.06.2017Examination requested  [2017/41]
11.10.2018Amendment by applicant (claims and/or description)
11.04.2019Despatch of a communication from the examining division (Time limit: M02)
10.06.2019Reply to a communication from the examining division
09.03.2020Communication of intention to grant the patent
21.07.2020Application deemed to be withdrawn, date of legal effect  [2020/53]
11.08.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2020/53]
Fees paidRenewal fee
12.12.2017Renewal fee patent year 03
12.12.2018Renewal fee patent year 04
13.12.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]  - "Rattus norvegicus dopamine D2 receptor gene, promoter region and exon 1.", ENA, (19970202), Database accession no. U79717.1, XP002778777 [Y] 1-15 * the whole document *
 [Y]  - TORU TATENO ET AL, "Differential Expression of Somatostatin and Dopamine Receptor Subtype Genes in Adrenocorticotropin (ACTH)-secreting Pituitary Tumors and Silent Corticotroph Adenomas", ENDOCRINE JOURNAL, JP, (20090101), vol. 56, no. 4, doi:10.1507/endocrj.K08E-186, ISSN 0918-8959, pages 579 - 584, XP055456366 [Y] 1-15 * abstract and page 583 *

DOI:   http://dx.doi.org/10.1507/endocrj.K08E-186
 [Y]  - Q Cordeiro, "Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia", (20090601), URL: http://www.ncbi.nlm.nih.gov/pubmed/19547807, (20180305), XP055456358 [Y] 1-15 * whole document esp. abstract and pages 193-194 *
International search[A]  - "Rattus norvegicus clone CH 230-11B15. WORKING DRAFT SEQUENCE", GenBank, (20030510), Database accession no. AC096118.6, XP055448852 [A] 1-4, 24-25 * Entire document *
 [A]  - "Rattus norvegicus dopamine D2 receptor gene , promoter region and exon 1.", Genbank, (19970131), Database accession no. U79717.1, XP055448932 [A] 1-4, 24-25 * Entire document *
 [A]  - STONEHOUSE et al., "Caffeine Regulates Neuronal Expression of the Dopamine 2 Receptor Gene .", Mol Pharmacol, (20030000), vol. 64, no. 6, pages 1463 - 1473, XP055448938 [A] 1-4, 24-25 * , pg 1465, col 2, para 3, pg 1466, col 2, para 3 and pg 1468, col 1 para 1, Fig. 4 *

DOI:   http://dx.doi.org/10.1124/mol.64.6.1463
by applicant   - "GenBank", Database accession no. NM_012547
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.